Dare Bioscience (NASDAQ:DARE – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Profitability
This table compares Dare Bioscience and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dare Bioscience | -748.97% | -790.40% | -40.40% |
| Jaguar Animal Health | -179.03% | N/A | -136.47% |
Analyst Ratings
This is a breakdown of recent recommendations for Dare Bioscience and Jaguar Animal Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dare Bioscience | 1 | 0 | 3 | 0 | 2.50 |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
Dare Bioscience currently has a consensus target price of $5.00, indicating a potential upside of 1,126.99%. Given Dare Bioscience’s stronger consensus rating and higher possible upside, equities analysts plainly believe Dare Bioscience is more favorable than Jaguar Animal Health.
Institutional and Insider Ownership
6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 3.4% of Dare Bioscience shares are owned by insiders. Comparatively, 0.1% of Jaguar Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Dare Bioscience and Jaguar Animal Health”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dare Bioscience | $1.03 million | 7.78 | -$13.40 million | ($0.60) | -0.68 |
| Jaguar Animal Health | $11.51 million | 0.26 | -$53.43 million | ($3,731.34) | -0.00 |
Dare Bioscience has higher earnings, but lower revenue than Jaguar Animal Health. Dare Bioscience is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Dare Bioscience has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500.
Summary
Dare Bioscience beats Jaguar Animal Health on 9 of the 14 factors compared between the two stocks.
About Dare Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.
About Jaguar Animal Health
Jaguar Health, Inc., formerly Jaguar Animal Health, develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree. Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
